|
|
|
|
|
 |
|
 |
 |
 |
 |
 |
 |
 |
|
|
|
 Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. Our goal is to build a broad portfolio of products through a combination of internal development and acquisition/in-licensing activities and to utilize our specialty sales force to promote products in our target markets. We apply novel formulations and drug delivery technologies to known drug compounds, and compounds with the same mechanism of action or similar chemical structure as marketed products, to improve patient care by improving efficacy, reducing adverse side effects or increasing patient compliance relative to existing therapies. Based in Palo Alto, California, the company is committed to working closely with patients, patient advocacy groups and healthcare professionals.
 11/20/2008 | Press Release JAZZ PHARMACEUTICALS AND UCB ANNOUNCE POSITIVE PHASE III RESULTS FOR SODIUM OXYBATE (JZP-6) IN FIBROMYALGIA 11/19/2008 | Press Release JAZZ PHARMACEUTICALS CANCELS PRESENTATION PLANNED FOR NOVEMBER 19, 2008 AT LAZARD CAPITAL MARKETS 5TH ANNUAL HEALTHCARE CONFERENCE 11/13/2008 | Press Release JAZZ PHARMACEUTICALS, INC. ANNOUNCES THIRD QUARTER 2008 FINANCIAL RESULTS 11/10/2008 | Press Release JAZZ PHARMACEUTICALS, INC. TO ANNOUNCE THIRD QUARTER FINANCIAL RESULTS ON NOVEMBER 13, 2008 11/04/2008 | Press Release JAZZ PHARMACEUTICALS TO PRESENT AT INVESTOR CONFERENCES 10/06/2008 | Press Release JAZZ PHARMACEUTICALS TO PRESENT AT NATIXIS BLEICHROEDER HIDDEN GEMS HEALTHCARE CONFERENCE 09/11/2008 | Press Release JAZZ PHARMACEUTICALS, INC. ANNOUNCES FINAL PATIENT HAS COMPLETED PHASE III CLINICAL TRIAL OF SODIUM OXYBATE TO TREAT FIBROMYALGIA 07/24/2008 | Press Release JAZZ PHARMACEUTICALS, INC. TO ANNOUNCE SECOND QUARTER RESULTS ON AUGUST 7, 2008 07/21/2008 | Press Release JAZZ PHARMACEUTICALS ANNOUNCES CLOSING OF REGISTERED DIRECT OFFERING 07/16/2008 | Press Release JAZZ PHARMACEUTICALS ANNOUNCES $26.0 MILLION REGISTERED DIRECT OFFERING 06/11/2008 | Press Release JAZZ PHARMACEUTICALS FILES FORM S-3 REGISTRATION STATEMENTS |
|
© 2008 Jazz Pharmaceuticals, Inc. : Privacy Policy & Terms of Use | |
|
About Us : Our Products : News & Meetings : Partnering : Investors : Careers : Contact Us : Site Map | |
